title: Down-regulation of Sphk2 suppresses bladder cancer progression.
abstract: Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China. The abnormal expression of sphingosine kinase 2 (SphK2) is associated with tumor progression and a poor patient survival rate, however, the effect of SphK2 on the bladder cancer cells remains unclear. The aim of the paper was to study the expression of SphK2 in bladder cancer and the role of SphK2 on the cell proliferation, metastasis, and apoptosis in bladder cancer in vitro. Our results showed that SphK2 is up-regulated in bladder cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of SphK2 was significantly higher in human bladder cancer cells in comparison with normal bladder epithelial cells. Silencing of SphK2 could inhibit the proliferation ability of T24 cells in vitro. In addition, SphK2 knockdown could induce a significant increase in the number of apoptotic cells. Furthermore, the transwell assay also showed significant cell migration inhibition in SphK2 siRNA transfectant compared with cell lines transfected with NC. Thus, this study suggested that SphK2 inhibition may provide a promising treatment for bladder cancer patients.
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China. irene_sunsun@yahoo.com.
authors.forename: Erlin
authors.initials: E
authors.lastname: Sun
authors.affiliation: School of life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, China.
authors.forename: Wenbo
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Lining
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Aixiang
authors.initials: A
authors.lastname: Wang
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Chengquan
authors.initials: C
authors.lastname: Ma
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Mingde
authors.initials: M
authors.lastname: Lei
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Bingxin
authors.initials: B
authors.lastname: Lu
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Liwei
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin, People's Republic of China.
authors.forename: Ruifa
authors.initials: R
authors.lastname: Han
mesh_terms: D017209:Apoptosis; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D018450:Disease Progression; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020128:Inhibitory Concentration 50; D009362:Neoplasm Metastasis; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000378:metabolism; D015854:Up-Regulation; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology*; D000099157:Sphingosine Kinase
chemical_list: D017853:Phosphotransferases (Alcohol Group Acceptor); D034741:RNA, Small Interfering; C000594250:sphingosine kinase 2, human; D000099157:Sphingosine Kinase
keywords: Apoptosis; Bladder cancer; Migration; Proliferation; SphK2